SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On June 19, 2019, Sorrento Therapeutics, Inc. (“Sorrento”) issued a press release providing updates regarding its CD38 immunotherapies. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
On June 19, 2019, Sorrento issued a press release announcing certain results from its Phase 1b clinical trial of resiniferatoxin (RTX) in knee osteoarthritis pain. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.
The information contained in this Item 7.01 and Exhibits 99.1 and 99.2 hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.
Item 8.01 Other Information.
On June 19, 2019, Sorrento posted under the “Investors” section of Sorrento’s website at www.sorrentotherapeutics.com a corporate presentation regarding its CD38 immunotherapies. Representatives of Sorrento will use the presentation in industry conferences, investor conferences and investor meetings from time to time. A copy of the presentation is filed as Exhibit 99.3 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibit.
| 99.1 | Press Release (CD38 Immunotherapies), dated June 19, 2019. |
| 99.2 | Press Release (RTX), dated June 19, 2019. |
| 99.3 | CD38 Immunotherapies Corporate Presentation. |
Sorrento Therapeutics, Inc. Exhibit
EX-99.1 2 tv523828_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE June 19th,…
To view the full exhibit click here
About SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE)
Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.